Search results
Sep 2, 2020 · These studies suggest a link between COVID-19 and GBS. At the time of writing this paper, approximately 31 cases of GBS associated with COVID-19 infection have been reported. This study showed that, on average, 11.92 ± 6.20 days after COVID-19 infection, the neurological symptoms of GBS begin.
Oct 18, 2023 · Existing data regarding occurrence of Guillain-Barré syndrome (GBS) after coronavirus disease 2019 (COVID-19) infection and vaccination are inconclusive. We aimed to assess the association between GBS and both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 vaccine.
Sep 7, 2021 · Central nervous system complications are reported in an increasing number of patients with Coronavirus Disease 2019 (COVID-19). COVID-19–related Guillain-Barré syndrome (GBS) is of particular importance given its association with higher mortality rates and prolonged respiratory failure.
Guillain-Barré syndrome (GBS), an immune-mediated polyradiculoneuropathy with a ≈5% mortality rate, has an incidence worldwide of 0.81–1.91 cases/100,000 person-years ( 1 ). GBS has been reported to be associated with coronavirus disease (COVID-19) vaccination, but a comprehensive summary regarding this rare adverse event is still lacking.
Oct 19, 2023 · A large new study links COVID-19 with an increased risk of Guillain-Barré syndrome (GBS). Vaccination against COVID appeared to reduce the risk of GBS, which is a rare illness that can...
In this cohort study’s interim analyses conducted in a large population-based surveillance system that included medical record review of all potential GBS cases after COVID-19 vaccination through November 13, 2021, findings were consistent with an increased risk of GBS after Ad.26.COV2.S.
Apr 17, 2020 · Five patients who had Guillain–Barré syndrome 5 to 10 days after the onset of Covid-19 are described. Three had severe weakness and an axonal pattern on electrophysiological studies, and...
